DekaBank Deutsche Girozentrale bought a new position in Morphic Holding, Inc. (NASDAQ:MORF – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,000 shares of the company’s stock, valued at approximately $698,000.
Other large investors have also added to or reduced their stakes in the company. Advisor Group Holdings Inc. bought a new position in Morphic in the 4th quarter worth about $25,000. Tower Research Capital LLC TRC boosted its stake in Morphic by 63.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 951 shares of the company’s stock worth $36,000 after purchasing an additional 369 shares during the period. UBS Group AG bought a new position in Morphic in the 1st quarter worth about $54,000. Group One Trading L.P. bought a new position in Morphic in the 1st quarter worth about $56,000. Finally, SG Americas Securities LLC bought a new stake in shares of Morphic during the 2nd quarter valued at about $111,000. Institutional investors own 80.66% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. BMO Capital Markets dropped their price target on Morphic from $106.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday, September 28th. Stifel Nicolaus dropped their price target on Morphic from $61.00 to $33.00 and set a “hold” rating for the company in a research report on Monday, September 25th. TheStreet downgraded Morphic from a “c-” rating to a “d+” rating in a research report on Wednesday, August 9th. Berenberg Bank started coverage on Morphic in a research report on Friday, July 21st. They set a “buy” rating and a $75.00 price target for the company. Finally, BTIG Research cut Morphic from a “buy” rating to a “neutral” rating in a report on Monday, September 25th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.71.
Morphic Trading Down 1.2 %
Shares of NASDAQ MORF opened at $21.63 on Monday. The stock’s 50-day moving average is $44.25 and its 200 day moving average is $50.03. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -6.68 and a beta of 1.33. Morphic Holding, Inc. has a 1-year low of $19.80 and a 1-year high of $63.08.
Morphic (NASDAQ:MORF – Get Free Report) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.02). Morphic had a negative return on equity of 27.71% and a negative net margin of 92.38%. On average, analysts forecast that Morphic Holding, Inc. will post -3.83 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Praveen P. Tipirneni sold 3,597 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $57.04, for a total transaction of $205,172.88. Following the transaction, the chief executive officer now directly owns 13,936 shares of the company’s stock, valued at $794,909.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Marc Schegerin sold 20,000 shares of Morphic stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $54.34, for a total transaction of $1,086,800.00. Following the sale, the chief financial officer now directly owns 24,136 shares in the company, valued at $1,311,550.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Praveen P. Tipirneni sold 3,597 shares of Morphic stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $57.04, for a total value of $205,172.88. Following the sale, the chief executive officer now owns 13,936 shares in the company, valued at $794,909.44. The disclosure for this sale can be found here. Insiders own 28.10% of the company’s stock.
Morphic Company Profile
Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.
See Also
- Five stocks we like better than Morphic
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- MarketBeat Week in Review – 10/9 – 10/13
- What Are Meme Stocks and Are They Viable Investments?
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- How Technical Indicators Can Help You Find Oversold Stocks
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.
